Bibliographic database on neuromuscular diseases

  sorted by (Issue date descending, Issue date descending, System of projection of the document ascending) 

Article

Frontiers in neurology, 14. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Howard JF ; Bril V ; Vu T ; Karam C ; Peric S ; De Bleecker JL ; Murai H ; Meisel A ; Beydoun SR ; Pasnoor M ; Guglietta A ; Van Hoorick B ; Steeland S ; T'joen C ; Utsugisawa K ; Verschuuren J ; Mantegazza R | 2023

More information...

Add to the basket

Link for e-copy:

Article

The Lancet. Neurology, 20, 7. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Howard Jr JF ; Bril V ; Vu T ; Karam C ; Peric S ; Margania T ; Murai H ; Bilinska M ; Shakarishvili R ; Smilowski M ; Guglietta A ; Ulrichts P ; Vangeneugden T ; Utsugisawa K ; Verschuuren J ; Mantegazza R | England | 07/2021

More information...

Add to the basket

Link for e-copy:

Article

Neurology, 92, 24. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Howard Jr JF, Author ; Bril V ; Burns TM ; Mantegazza R ; Bilinska M ; Szczudlik A ; Beydoun S ; Garrido FJRR ; Piehl F ; Rottoli M ; Van Damme P ; Vu T ; Evoli A ; Freimer M ; Mozaffar T ; Ward ES ; Dreier T ; Ulrichts P ; Verschueren K ; Guglietta A ; De Haard H ; Leupin N ; Verschuuren JJGM | 04/06/2019

More information...

Add to the basket

Link for e-copy: